FDMT | 4D Molecular Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.74 - 6.37
52 Week Range	5.58 - 36.25
Beta	3.07
Implied Volatility	190.40%
IV Rank	52.85%
Day's Volume	4,613,743
Average Volume	892,098
Shares Outstanding	46,227,700
Market Cap	291,696,787
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-11

Valuation
Profitability
Growth
Health
P/E Ratio	-2.21
Forward P/E Ratio	N/A
EPS	-2.85
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	147
Country	USA
Website	FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

FDMT's peers: ACIU, ALVR, ARCT, DNLI, TCRR, RVMD, BDTX, BCEL, PASG, IPSC, EWTX, CCCC, MLYS, CGEM, BMEA, STOK, AKRO, FIXX, GOSS, REPL, NVCT, LYRA, KRON, RGNX, SYBX, ZVRA

*Chart delayed

Analyzing fundamentals for FDMT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see FDMT Fundamentals page.

Watching at FDMT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on FDMT Technicals page.